Scholarlink

Purpose <p>To study the association between [<sup>18</sup>F]FAPI- 04 uptake on positron emission tomography/computed tomography (PET/CT) and pathologic treatment response (PTR) in patients with pancreatic cancer (PC).</p> Methods <p>We enrolled 59 patients from August 2021, of whom 28 underwent surgical treatment after systemic therapy. The patients were investigated for a correlation between baseline fibroblast activation protein inhibitor (FAPI) uptake and PTR using College of American Pathologists (CAP) scores. The FAPI PET variables include standardised uptake value (SUV)max, SUVmean, metabolic tumour volume (MTV), and total lesion FAP expression (TLF). A PET/CT scan obtained before surgery in 14 patients facilitated assessing changes in FAPI uptake through treatment, and their association with PTR. Multiplex immunohistochemistry (mIHC) analysis identified the FAPI biodistribution in the PC tumours.</p> Results <p>The SUVmax correlated positively with FAP expression in PC tissues. However, there was no correlation between baseline variables and the CAP scores. Treatment resulted in remarkably reduced MTV and TLF in all patients. The baseline SUVmax and SUVmean of patients with a good PTR (CAP score ≤ 2) differed from those after treatment (<i>p</i> = 0.001). An FITC-FAPI probe intuitively showed that cancer-associated fibroblasts (CAFs) and tumour cells had a similar FITC-FAPI fluorescence intensity, indicating a negative association between tumour regression and [<sup>18</sup>F]FAPI- 04 uptake.</p> Conclusion <p>Greater changes in FAPI uptake through treatment were associated with a better PTR in patients with PC and might be valuable in predicting prolonged survival. These results are clinically meaningful when selecting candidates for conversion surgery during systemic treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

[18F]FAPI- 04 PET/CT for pathologic response assessment in pancreatic cancer patients with systemic treatment

  • 期刊论文

  • 发表日期：

    2025年4月16日

查看全文
  • Xiang Li,
  • Na Lu,
  • Kang Sun,
  • Fukang Shi,
  • Lili Lin,
  • Yiwen Chen,
  • Yangyang Wang,
  • Meng Wang,
  • Ke Sun,
  • Xing Xue,
  • Wenbo Xiao,
  • Xinhui Su,
  • Xueli Bai,
  • Tingbo Liang

摘要

Purpose

To study the association between [18F]FAPI- 04 uptake on positron emission tomography/computed tomography (PET/CT) and pathologic treatment response (PTR) in patients with pancreatic cancer (PC).

Methods

We enrolled 59 patients from August 2021, of whom 28 underwent surgical treatment after systemic therapy. The patients were investigated for a correlation between baseline fibroblast activation protein inhibitor (FAPI) uptake and PTR using College of American Pathologists (CAP) scores. The FAPI PET variables include standardised uptake value (SUV)max, SUVmean, metabolic tumour volume (MTV), and total lesion FAP expression (TLF). A PET/CT scan obtained before surgery in 14 patients facilitated assessing changes in FAPI uptake through treatment, and their association with PTR. Multiplex immunohistochemistry (mIHC) analysis identified the FAPI biodistribution in the PC tumours.

Results

The SUVmax correlated positively with FAP expression in PC tissues. However, there was no correlation between baseline variables and the CAP scores. Treatment resulted in remarkably reduced MTV and TLF in all patients. The baseline SUVmax and SUVmean of patients with a good PTR (CAP score ≤ 2) differed from those after treatment (p = 0.001). An FITC-FAPI probe intuitively showed that cancer-associated fibroblasts (CAFs) and tumour cells had a similar FITC-FAPI fluorescence intensity, indicating a negative association between tumour regression and [18F]FAPI- 04 uptake.

Conclusion

Greater changes in FAPI uptake through treatment were associated with a better PTR in patients with PC and might be valuable in predicting prolonged survival. These results are clinically meaningful when selecting candidates for conversion surgery during systemic treatment.